ACH — Accendra Health, Inc.

Summary of Accendra Health's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Reported a decline of 6.8% year-over-year. Excluding the impact of exiting a large commercial payor, revenue growth would have been approximately 1%.
• Adjusted EBITDA: $58 million, consistent with expectations despite a lower year-over-year collection rate and inflationary pressures.
• Cash Flow: Free cash flow was slightly negative due to typical seasonal softness and extraordinary payments totaling $41 million related to tax matters and divestiture costs.
• Net Debt: Remained flat at $1.77 billion, with $337 million in cash and $195 million available under a revolving credit facility.

2. Strategic Updates and Business Highlights

• Transition from Owens & Minor: Successfully completed separation activities, allowing Accendra to operate independently.
• Payor Agreements: Secured a multiyear extension with the largest commercial payor for soft goods, enhancing revenue stability.
• Sleep Therapy Initiatives: The Sleep Journey program and the newly launched Sleep Center of Excellence are expected to improve patient adherence and operational efficiency, with a nationwide rollout planned.
• Balance Sheet Optimization: Announced a comprehensive transaction to extend maturities and reduce debt, enhancing financial flexibility and liquidity.

3. Forward Guidance and Outlook

• 2026 Outlook: The company reaffirms its revenue and adjusted EBITDA guidance, anticipating stronger growth in the latter half of the year.
• Growth Expectations: Projecting mid-single-digit revenue growth and slight EBITDA margin improvements in 2027, though cautioning against over-reliance on these figures until further analysis is completed.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant drop in revenue due to the exit from a large commercial payor raises concerns about the sustainability of growth.
• Cost Pressures: Higher health benefit expenses and inflationary product costs are impacting margins, despite ongoing cost-saving efforts.
• Market Dynamics: The diabetes segment is facing price compression, particularly in Continuous Glucose Monitoring (CGM) products, which could affect future growth.
• Transition Risks: While the transition away from the large payor was managed well, any future disruptions in payor relationships could pose risks.

5. Notable Q&A Insights

• Free Cash Flow Management: Management indicated that any generated cash flow will be directed towards debt reduction, with specific forecasts pending the completion of financing activities.
• Diabetes Market Positioning: The company sees potential in the Durable Medical Equipment (DME) channel for diabetes management, emphasizing the importance of patient education to improve adherence rates.
• Sleep Initiatives Performance: The Sleep Journey program has shown consistent improvement in adherence rates, with the Sleep Center of Excellence expected to enhance patient experience and operational efficiency.
• Debt Refinancing Timeline: The debt refinancing is expected to be completed by mid to late June, which will alleviate concerns regarding near-term maturities.

Overall, Accendra Health is navigating a transformative period with a focus on improving operational efficiency and financial stability, while also addressing challenges in revenue growth and market dynamics.